Mon, March 26, 2012
Sun, March 25, 2012
Sat, March 24, 2012
Fri, March 23, 2012
Thu, March 22, 2012
Wed, March 21, 2012
Tue, March 20, 2012
Mon, March 19, 2012
Sun, March 18, 2012
Fri, March 16, 2012
Thu, March 15, 2012
Wed, March 14, 2012
Tue, March 13, 2012
Mon, March 12, 2012

Tengion to Host Conference Call to Provide a Business Update and Report Fourth Quarter 2011 Financial Results on March 26, 2012


  Copy link into your clipboard //health-fitness.news-articles.net/content/2012/ .. ter-2011-financial-results-on-march-26-2012.html
  Print publication without navigation Published in Health and Fitness on by Market Wire


Tengion to Host Conference Call to Provide a Business Update and Report... -- WINSTON-SALEM, N.C., March 19, 2012 /PRNewswire/ --

Tengion to Host Conference Call to Provide a Business Update and Report Fourth Quarter 2011 Financial Results on March 26, 2012

[ ]

WINSTON-SALEM, N.C., March 19, 2012 /PRNewswire/ -- Tengion, Inc. (NASDAQ: [ TNGN ]), a leader in regenerative medicine, today announced it will host a conference call and live audio webcast on Monday, March 26, 2012, at 5:00 p.m. EDT to provide a business update and discuss its fourth quarter 2011 financial results.

To participate in the call, please dial 1-800-638-4930 (domestic) or 1-617-614-3944 (international) and reference access code 34844557.

The conference call can be accessed from the [ Investors ] section of the Company's website or directly at [ http://edge.media-server.com/m/p/o4v89uyi/lan/en ]. The webcast will also be archived on the website.

About Tengion

Tengion, a clinical-stage regenerative medicine company, is focused on discovering, developing, manufacturing and commercializing a range of neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ.  Using its Organ Regeneration Platform™, the Company creates neo-organs using a patient's own cells, or autologous cells.  Tengion's proprietary product candidates harness the intrinsic regenerative pathways of the body to regenerate a range of native-like organs and tissues.  The Company's product candidates are intended to delay or eliminate the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications.  An initial clinical trial is ongoing for the Company's lead product candidate, the Neo-Urinary Conduit™, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal. The Company's lead preclinical candidate is the Neo-Kidney Augment™, which is designed to prevent or delay dialysis by increasing renal function in patients with advanced chronic kidney disease. Tengion has worldwide rights to its product candidates.

 

SOURCE Tengion, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.tengion.com ]


Publication Contributing Sources

Publication Sponsors
[ Last Sunday ] - Oceanside Rental Gear